跳至主要内容
临床试验/NCT05466786
NCT05466786招募中不适用

Landscape Ofhomologous Recombination-related (HRR) Genes Mutations and HRD, and Correlation With Survival in HER2-lowbreast Cance

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1 个研究点 分布在 1 个国家目标入组 255 人开始时间: 2022年8月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
255
试验地点
1
主要终点
1.To assess the distribution characteristics of mHRR/HRD in breast cancer with low HRE2 expression in Chinese population

研究概览

简要总结

This is a cross-sectional and an observational study, investigator-initiated study in HER2-low breast cancer patients. Approximately 255 subjects with HRD (homologous recombination deficiency) assessment will be enrolled in this study to examine the distribution and features of HRD/HRR (homologous recombination repair).

In this study, investigators plan to clarify the frequency of HRR/HRD in Chinese patients with HER2-low breast cancer.

In addition, it is planned to investigate any association between invasive disease-free survival (iDFS)/overall survival (OS) and HRD/HRR in HER2-low breast cancer patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients aged 18-70 years with pathologically confirmed HER2-low breast cancer (defined as IHC 2+/ISH- or IHC 1+ per ASCO/CAP guidelines);
  • ECOG performance status of 0 or 1;
  • Treatment-naïve operable primary breast cancer with completed homologous recombination deficiency (HRD) assessment;
  • 5)Absence of distant metastasis; 6)Availability of adequate tumor tissue and blood samples for biomarker analysis.

排除标准

  • Recurrent or inoperable locally advanced breast cancer;
  • Bilateral breast cancer;
  • History of other malignant tumors within the past 5 years;
  • Incomplete clinical or pathological data.

结局指标

主要结局

1.To assess the distribution characteristics of mHRR/HRD in breast cancer with low HRE2 expression in Chinese population

时间窗: At the time of 4 weeks after surgery

the distribution and features of HRD /HRR is evaluated.

次要结局

  • To assess the clinical characteristics between patients with mutations and non-mutation(At the time of 4 weeks after surgery)
  • To compare the correlation between iDFS/OS and different adjuvant treatment regimens for breast cancer with low HER2 expression(At the time of 36 months after surgery)
  • To investigate the HRR/HRD characteristics and clinical characteristics (family history, age pathological feature es, etc.) of breast cancer patients with low HER2 expression(At the time of 4 weeks after surgery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chang Gong

Chief physician

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

研究点 (1)

Loading locations...

相似试验